CCL2 and neoplasm: The researchers found that EE downregulated CCL2 expression in tumor cells and tumor-associated immune cells through the peripheral neuroendocrine–immune pathway sympathetic nervous system (SNS)/β-adrenergic receptors (β-ARs)/CCL2.